CClinicalTrials.gg
CompletedNCT03551379Updated Aug 20, 2019

A Double Balloon Endoscopic Platform for ESD

An observational study in Colon Adenoma and Colon Polyp, sponsored by Lumendi, LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-20.

Sponsored by Lumendi, LLC · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
15
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this observational study is to record performance of a double balloon endolumenal interventional platform during complex colon polypectomy.

Read the detailed description

Endoscopic removal of Complex colon polyps (benign polyps >=2cm) is a technically challenging procedure. Complex benign polyps have a greater chance of becoming cancerous if not removed.

The DiLumen™ Endolumenal Interventional Platform is a non-sterile, single-use, close-fitting sleeve that fits securely over a standard endoscope to stabilize it in the large intestine, and facilitates use of the endoscope for optical visualization, diagnosis, and treatment. The device is indicated to ensure complete positioning of an endoscope in the large intestine and assist with optical visualization, diagnosis, and endoscopic treatment.

The device received 510k clearance on Dec 6, 2016. The study will evaluate performance of the device during routine, scheduled, endoscopic polyp removal for these large polyps.

02

Conditions studied

  • Colon Adenoma
  • Colon Polyp

Browse trials for

Keywords

  • Endoscopic Submucosal Dissection
03

In context

Adenoma

657 studies on the registry are indexed under Adenoma; 98 are open to participants now.

This study's enrollment of 15 is below the median of 300 across 226 observational studies indexed under Adenoma.

Browse Adenoma studies →

Lead sponsor

Lumendi, LLC is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with documented complex large intestinal polyps

Inclusion criteria

  • Subjects > 18 years of age
  • Subjects scheduled for endoscopic removal of suspected complex adenomatous polyps in the large intestine which are sessile or polypoid lesions ≥ 2cm, near the ileocecal valve, dentate line, over a fold, or at a flexure; and or lesions tethered to the colon wall due to previous incomplete resection
  • Subjects willing and able to give informed consent
  • Subjects who in the opinion of the Principal Investigator have no medical contraindication to endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD)

Exclusion criteria

Exclusion Criteria:

  • Subjects with a contraindication to colonoscopy, including but not limited to active colitis, perforation, or stricture.
  • Subjects with a history of open or laparoscopic colorectal surgery
  • Subjects with a history of Inflammatory Bowel Disease (IBD)
  • Subjects with a suspected malignancy on polyp assessment
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
15 participants (actual)
Patient registry
No

Groups and cohorts

  • Endoscopic procedure

    A double balloon endoscopic platform will be used during an ESD procedure

    Device: Double Balloon Endoluminal Platform

Interventions

  • DeviceDouble Balloon Endoluminal Platform

    A DBA platform will be use din this registry study to facilitate ESD

06

What researchers measure

Primary outcomes

  1. Ability to remove the complex polyp endoscopically

    Was the lesion(s) able to be removed using the DiLumen Endolumenal Interventional Platform Device \[Yes/No\]

    Time frame: Duration of Procedure

  2. Time taken for lesion removal

    Time for lesion(s) removal with the double balloon device after intervention begins

    Time frame: Intervention start time until Lesion removal

  3. Device or Procedural Adverse Events

    Colon perforation, colon mucosal injury, excess bleeding will be recorded

    Time frame: Up to 72 hours

07

Study locations

1 site
  • Winthrop-NYU Langone
    Mineola, New York 11501, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03551379
Lead sponsor
Lumendi, LLC
Responsible party
Sponsor
First posted
Jun 11, 2018
Start date
Sep 22, 2017
Primary completion
Mar 9, 2018
Completion
Sep 29, 2018
Last update
Aug 20, 2019

Study contacts

Stavros Stavropoulos, MD
principal investigator · Winthrop-NYU Langone Mineola, NY

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion